CY1807A - Treatment of androgenic alopecia with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones - Google Patents

Treatment of androgenic alopecia with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones

Info

Publication number
CY1807A
CY1807A CY180795A CY180795A CY1807A CY 1807 A CY1807 A CY 1807A CY 180795 A CY180795 A CY 180795A CY 180795 A CY180795 A CY 180795A CY 1807 A CY1807 A CY 1807A
Authority
CY
Cyprus
Prior art keywords
5alpha
17beta
androst
monosubstituted
aza
Prior art date
Application number
CY180795A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21878727&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1807(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of CY1807A publication Critical patent/CY1807A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/16—Benz[e]indenes; Hydrogenated benz[e]indenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CY180795A 1987-04-03 1995-09-08 Treatment of androgenic alopecia with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones CY1807A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3480687A 1987-04-03 1987-04-03

Publications (1)

Publication Number Publication Date
CY1807A true CY1807A (en) 1995-09-08

Family

ID=21878727

Family Applications (1)

Application Number Title Priority Date Filing Date
CY180795A CY1807A (en) 1987-04-03 1995-09-08 Treatment of androgenic alopecia with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones

Country Status (5)

Country Link
EP (1) EP0285382B1 (fr)
CA (1) CA1302277C (fr)
CY (1) CY1807A (fr)
DE (1) DE3888994T2 (fr)
HK (1) HK116494A (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992002225A1 (fr) * 1990-08-10 1992-02-20 The Upjohn Company STIMULATION DE LA CROISSANCE CAPILLAIRE AU MOYEN D'AGENTS D'OUVERTURE DES CANAUX DE POTASSIUM ET D'INHIBITEURS DE 5α-REDUCTASE
HU212459B (en) * 1992-10-02 1996-06-28 Richter Gedeon Vegyeszet Process for producing new 17-beta-substituted 4-aza-androstane-derivatives and pharmaceutical compositions containing them
GB2274060A (en) * 1993-01-07 1994-07-13 Merck & Co Inc Treatment of patterned alopecia with 17ß-acyl-4-aza-5-androst-1-ene-3-ones and minoxidil
US5359071A (en) * 1993-03-12 1994-10-25 Merck & Co., Inc. 15-substituted 4-azasteroids
WO1994022900A1 (fr) * 1993-04-02 1994-10-13 Ciba-Geigy Ag AZA-ANDROSTANE-17β-CARBOXAMIDES
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
TW382595B (en) * 1993-10-15 2000-02-21 Merck & Co Inc Pharmaceutical composition for use in arresting and reversing androgenic alopecia
AU700565B2 (en) * 1993-10-15 1999-01-07 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitor formulations
RU2173152C2 (ru) * 1993-10-15 2001-09-10 Мерк Энд Ко., Инк. Способ лечения андрогенной алопеции ингибиторами 5-альфа-редуктазы
US5547957A (en) * 1993-10-15 1996-08-20 Merck & Co., Inc. Method of treating androgenic alopecia with 5-α reductase inhibitors
KR100363994B1 (ko) * 1993-10-21 2003-04-10 머크 앤드 캄파니 인코포레이티드 16-치환된-4-아자-안드로스탄5-알파-리덕타제아이소자임1억제제
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
US5656613A (en) * 1995-01-04 1997-08-12 Merck & Co., Inc. Treatment of hyperandrogenic conditions
JPH11513380A (ja) * 1995-09-27 1999-11-16 メルク エンド カンパニー インコーポレーテッド ５−αレダクターゼ阻害剤によるアンドロゲン性脱毛症の予防方法
IL124764A0 (en) * 1998-06-04 1999-01-26 Univ Ben Gurion Topical composition for treatment of baldness
BR0309435A (pt) 2002-04-24 2005-02-15 Boehringer Ingelheim Pharma Combinação farmacêutica para o tratamento de hiperplasia prostática benigna ou para a prevenção a longo prazo de retenção urinária aguda
PL1644024T3 (pl) 2003-06-06 2020-03-31 Board Of Regents, The University Of Texas System Przeciwdrobnoustrojowe roztwory do płukania
ES2834006T3 (es) 2008-09-27 2021-06-16 Jina Pharmaceuticals Inc Preparados farmacéuticos a base de lípidos para aplicación tópica

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU527030B2 (en) * 1978-04-13 1983-02-10 Merck & Co., Inc. 4-aza-17-substituted-5a-androstan-3-ones
NZ211145A (en) * 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions

Also Published As

Publication number Publication date
EP0285382B1 (fr) 1994-04-13
HK116494A (en) 1994-11-04
EP0285382A3 (en) 1990-09-12
EP0285382A2 (fr) 1988-10-05
DE3888994D1 (de) 1994-05-19
CA1302277C (fr) 1992-06-02
DE3888994T2 (de) 1994-11-03

Similar Documents

Publication Publication Date Title
GB8716133D0 (en) Treatment of materials
EP0285382A3 (en) Treatment of androgenic alopecia with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones
GB8704089D0 (en) Method of treatment
EP0278726A3 (en) Treatment of alkoxysilanes
GB8707932D0 (en) Treatment of hair
SG128794G (en) Treatment of androgenic alopecia with 17 beta-N-monosubstituted-carbamoyl-4-aza-5 alpha-androst-1-en-3-ones
GB8311207D0 (en) Treatment of alopecia
GB8826065D0 (en) After treatment of dyed substrates
GB8707427D0 (en) Treatment of dandruff
GB8602313D0 (en) Reduction of photo-yellowing
JPS57175116A (en) Pharmacological composition for circular alopecia treatment and therapy thereby
BG42381A1 (en) Means for treatment of psrriasis vulgaris
GB8704172D0 (en) Treatment of wool
GB8721773D0 (en) Treatment of fibres
GB8704090D0 (en) Method of treatment
GB8704088D0 (en) Method of treatment
GB8718025D0 (en) Method of treatment
BG46628A1 (en) Means for treatment of artrose alterations
GB8618949D0 (en) Method of treatment
BG40988A1 (en) Means for prophylaxy and treatment of seboreic state
BG41322A1 (en) Means for treatment of rhinitis and rhinopathies
GB8822014D0 (en) Method of treatment
GB8812232D0 (en) Method of treatment
GB8812226D0 (en) Method of treatment
GB8812225D0 (en) Method of treatment